Filing Flows › Supernus Pharmaceuticals (SUPN) › Q1 2025
Supernus Pharmaceuticals (SUPN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Supernus Pharmaceuticals (SUPN) reported revenue of $150M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -14% from the quarter before. Operating margin was -6.8%, net loss $11.8M (7.9% of revenue).
Supernus Pharmaceuticals, Q1 2025: revenue $150M (+4% year over year), operating margin -6.8%, net loss $11.8M, operating cash flow $30.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $150M | -14% | +4% |
| Operating profit | −$10.3M | — | — |
| Net earnings | −$11.8M | — | — |
| Operating cash flow | $30.6M | -31% | -20% |
| Free cash flow | $30.3M | -32% | -21% |
What changed
Revenue was $149.8M in Q1 2025, up 4% year over year and down 14% from the previous quarter. Qelbree was the largest line at 43% of revenue. Qelbree added $19.6M year over year (up 44%), 318% of the total change. Oxtellar XR declined 62%.
Operating costs exceeded revenue by $10.3M, an operating margin of -6.8%. Total costs grew 9% against revenue growth of 4%. The fastest-growing cost line was Other operating costs (+44%). The quarter ended with a net loss of $11.8M, after a profit of $15.3M the previous quarter. Non-operating items added $4.4M, -76% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $30.6M (down 20% year over year). Non-cash charges added back $20.4M of depreciation and amortization and $8.1M of share-based compensation. Working capital and other items added $14.0M. Capital expenditures of $327K left free cash flow of $30.3M.
Questions
What was Supernus Pharmaceuticals' revenue in the first quarter 2025?
Supernus Pharmaceuticals (SUPN) reported revenue of $150M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -14% from the quarter before.
Was Supernus Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $10.3M (-6.8% of revenue) and net loss $11.8M.